Merck Group → highlights of 2014
Subsequent to a doubling in the value of Merck shares since the beginning of 2011, Merck announces a share split in a ratio of 1: 2. The share split became effective on June 30.
Through the acquisition of AZ for around € 1.9 billion, Merck expands its existing, highly profitable Liquid Crystals business with high-tech electronic materials. AZ materials are widely used in integrated circuits, flat-panel displays and light-emitting diodes, making AZ an important partner to the leading global electronic manufacturers.
Marcus Kuhnert joins Merck as Member of the Executive Board and Chief Financial Officer.
Merck holds the groundbreaking ceremony for its new pharmaceutical manufacturing site in Nantong, China. The new facility will be Merck’s second-largest worldwide. As of 2017, it will mainly focus on the bulk production and packaging of medicines referenced in China’s essential drug list.
The expansion of the Merck site in Darmstadt into a contemporary global headquarters is clearly taking shape. The symbolic groundbreaking officially marks the launch of the “ONE Global Headquarters” project.
Effective January 1, 2015, Stefan Oschmann becomes Vice Chairman of the Executive Board. On the same date, Belén Garijo becomes a Member of the Executive Board and assumes the leadership of the Healthcare business sector.
Merck announces an agreement to acquire Sigma-Aldrich for US$ 17.0 billion. The combination would establish one of the leading players in the US$ 130 billion global life science industry. On December 5, Sigma-Aldrich shareholders approve the merger with Merck.
Merck kicks off a global communications campaign called “Proud to be an Original”. The campaign offers Merck’s 39,000 employees worldwide the opportunity to express their pride in working for Merck.
Merck and Pfizer will jointly develop and commercialize a highly promising anti-PD-L1 antibody from the Merck research pipeline. In value terms, the transaction is the largest so far in the biopharmaceutical industry for a single asset at this stage of development. Immuno-oncology is about mobilizing the body’s own immune system to fight tumor cells.